Novel targeted therapies for eosinophilic disorders

被引:85
作者
Wechsler, Michael E. [1 ]
Fulkerson, Patricia C. [2 ]
Bochner, Bruce S. [3 ]
Gauvreau, Gail M. [4 ]
Gleich, Gerald J. [5 ]
Henkel, Tim [6 ]
Kolbeck, Roland [7 ]
Mathur, Sameer K. [8 ]
Ortega, Hector [9 ]
Patel, Jatin [10 ]
Prussin, Calman [11 ]
Renzi, Paolo [12 ]
Rothenberg, Marc E. [2 ]
Roufosse, Florence [13 ,14 ]
Simon, Dagmar [15 ]
Simon, Hans-Uwe [16 ]
Wardlaw, Andrew [17 ]
Weller, Peter F. [18 ]
Klion, Amy D. [19 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA
[2] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA
[4] McMaster Univ, Hamilton, ON L8S 4L8, Canada
[5] Univ Utah, Dept Dermatol & Med, Salt Lake City, UT USA
[6] Ceptaris Therapeut, Malvern, PA USA
[7] MedImmune Resp Inflammat & Autoimmun, Gaithersburg, MD USA
[8] Univ Wisconsin, Sch Med, Dept Med, Div Allergy Pulm & Crit Care, Madison, WI 53706 USA
[9] GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC USA
[10] GlaxoSmithKline Res & Dev Ltd, Uxbridge, Middx, England
[11] NIAID, Lab Allerg Dis, Bethesda, MD 20892 USA
[12] Univ Montreal, Notre Dame Hosp, Montreal, PQ H3C 3J7, Canada
[13] Univ Libre Bruxelles, Erasme Hosp, Dept Internal Med, Brussels, Belgium
[14] Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium
[15] Univ Hosp Bern, Dept Dermatol, Inselspital, Bern, Switzerland
[16] Univ Bern, Inst Pharmacol, CH-3012 Bern, Switzerland
[17] Univ Leicester, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England
[18] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA
[19] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Hypereosinophilic syndromes; eosinophil-associated gastrointestinal disorders; eosinophilic esophagitis; Churg-Strauss syndrome; IL-5; mepolizumab; reslizumab; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; ANTI-IL-5 MEPOLIZUMAB THERAPY; CHURG-STRAUSS-SYNDROME; T-CELL POPULATION; AIRWAY INFLAMMATION; PERIPHERAL-BLOOD; ANTI-INTERLEUKIN-5; ANTIBODY; INHIBITORY RECEPTORS; ALEMTUZUMAB THERAPY; MONOCLONAL-ANTIBODY;
D O I
10.1016/j.jaci.2012.07.027
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approved for other disorders. (J Allergy Clin Immunol 2012;130:563-71.)
引用
收藏
页码:563 / 571
页数:9
相关论文
共 50 条
  • [41] Targeted therapy in eosinophilic chronic obstructive pulmonary disease
    Fieldes, Mathieu
    Bourguignon, Chloe
    Assou, Said
    Nasri, Amel
    Fort, Aurelie
    Vachier, Isabelle
    De Vos, John
    Ahmed, Engi
    Bourdin, Arnaud
    ERJ OPEN RESEARCH, 2021, 7 (02)
  • [42] Eosinophilic disorders in children
    Amy Wagelie-Steffen
    Seema S. Aceves
    Current Allergy and Asthma Reports, 2006, 6 : 475 - 482
  • [43] Eosinophilic Gastrointestinal Disorders
    Nirmala Gonsalves
    Clinical Reviews in Allergy & Immunology, 2019, 57 : 272 - 285
  • [44] Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies
    Lucendo, Alfredo J.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (01) : 63 - 77
  • [45] Is there a Role for Anti-IL-5 Therapies in Eosinophilic Fascitis?
    Angelopoulos, Andreas
    Kouverianos, Ioannis
    Daoussis, Dimitrios
    MEDITERRANEAN JOURNAL OF RHEUMATOLOGY, 2023, 34 (04): : 414 - 417
  • [46] Updates on eosinophilic disorders
    Alexandar Tzankov
    Kaaren K. Reichard
    Robert P. Hasserjian
    Daniel A. Arber
    Attilio Orazi
    Sa A. Wang
    Virchows Archiv, 2023, 482 : 85 - 97
  • [47] Eosinophilic gastrointestinal disorders
    Assa'ad, Amal
    ALLERGY AND ASTHMA PROCEEDINGS, 2009, 30 (01) : 17 - 22
  • [48] Eosinophilic Gastrointestinal Disorders
    Gonsalves, Nirmala
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2019, 57 (02) : 272 - 285
  • [49] Eosinophilic Myeloid Disorders
    Noel, Pierre
    SEMINARS IN HEMATOLOGY, 2012, 49 (02) : 120 - 127
  • [50] Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples
    Combe, Bernard
    van Vollenhoven, Ronald
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (09) : 1433 - 1435